A Phase 3, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effects of Bexagliflozin Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin
Phase of Trial: Phase III
Latest Information Update: 03 Mar 2019
Price : $35 *
At a glance
- Drugs Bexagliflozin (Primary) ; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Theracos
- 17 Sep 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 22 Jan 2018 Status changed from recruiting to active, no longer recruiting.